X

Infosys Ltd Q3 FY24 Earnings Conference Call Insights

Key highlights from Infosys Ltd (INFY) Q3 FY24 Earnings Concall

  • Declining Revenue Growth
    • Reported a 1% decline in revenue QonQ and YonY in constant currency terms.
    • For the first three quarters of FY2024, revenue grew only 1.8% YonY in constant currency.
    • The company is seeing lower demand for digital transformation and more interest in cost optimization and efficiency programs.
    • Expects revenue growth for FY2024 to be 1.5-2% in constant currency, lowering its previous guidance.
  • Margin Improvement Efforts
    • Operating margin was 20.5% for the quarter, a decline of 70 bps sequentially.
    • The company is making progress on its margin improvement plan, Project Maximus.
    • Key drivers of the margin decline were salary increases, impact of a cyber incident, and lower volumes.
    • These were partially offset by benefits from higher utilization, lower SG&A expenses, and other cost optimization.
    • Remains confident that Project Maximus will drive margin expansion over time.
  • Record Large Deal Wins
    • Infosys signed $3.2 billion in large deals for the quarter, 71% of which was net new, including one mega deal.
    • Large deal value for the first three quarters stands at $13.2 billion, the highest ever.
    • 71% of large deals were net new wins, while renewals were lower than previous quarters.
    • Large deal wins are helping Infosys gain market share across industries like financial services, telecom, and high-tech.
  • Traction in AI
    • Seeing strong demand for its generative AI offering, Topaz.
    • Trained 100,000 employees on generative AI and is deploying use cases for clients.
    • Infosys is integrating Topaz into solutions combined with its Cobalt cloud capabilities.
  • Challenging Communication Sector Growth
    • Clients in communication sector face growth challenges due to pressure on IT spending.
    • Uncertainty remains around medium-term spending plans.
    • Clients prioritizing cost optimization and vendor consolidation.
    • Delayed decision making and project deferrals as clients conserve cash.
  • Margin Outlook
    • Operating margins declined 70 bps sequentially in Q3 to 20.5%.
    • Underlying margins remain resilient despite one-time impacts this quarter.
    • Confident about medium-term margin expansion from initiatives around automation, value-based pricing etc.
    • Margin guidance retained at 20-22% for FY24.
    • Less wage pressure expected going forward.
  • Client Spending Trends
    • Spending steady on recent cost takeout and other projects signed in last 6-9 months.
    • Incremental project spending slowing in line with market conditions.
    • No major changes in broader client spending behavior.
  • Geography Trends
    • Europe growth strong in Q3, North America weaker.
    • Healthy large deal pipeline in both regions.
    • Current growth trends expected to continue near-term.
  • Pricing Trends
    • Seeing improved pricing stability compared to past years.
    • Conscious pricing through value-based selling initiatives.
    • No significant additional pricing pressure on renewals or large deals.
  • Platform Business Trends
    • Clinical platform business continues to see good traction.
    • However, overall platform business revenue flat last 2 years.
    • Platforms used extensively for internal productivity and services.
  • Revenue Growth Expectations
    • Environment remains uncertain in near term.
    • Digital transformation demand needs to pick up.
  • Headcount and Utilization
    • Optimized headcount with utilization levels having room.
    • Comfortable fulfilling demand given fresher hiring and availability of lateral talent.
    • Decline in headcount not a concern given levers at disposal.
    • Utilization improvement a potential source of margin upside.
Related Post